Table 1 Summary of patient characteristics for the study cohort
| Â | Study cohort | |
|---|---|---|
| Â | n | % |
Randomised treatment | ||
 E-CMF | 1156 | 19 |
 CMF | 1149 | 19 |
 EC-T | 1773 | 28 |
 EC-TG | 1769 | 28 |
 T-EC | 200 | 3 |
 TG-EC | 201 | 3 |
Age, years | ||
 ≤ 50 | 3606 | 58 |
 > 50 | 2642 | 42 |
ER status | ||
 Negative | 2551 | 41 |
 Positive | 3591 | 57 |
 Missing | 106 | 2 |
pGR status | ||
 Negative | 2463 | 39 |
 Positive | 2652 | 43 |
 Missing | 1133 | 18 |
HER2 status | ||
 Negative | 3760 | 60 |
 Positive | 1034 | 17 |
 Missing | 1454 | 23 |
Nodal status | ||
 Negative | 1366 | 22 |
 1–3 positive | 2383 | 38 |
 Clinically negative, neoadjuvant | 409 | 7 |
 Clinically positive, neoadjuvant | 403 | 6 |
 4+ positive | 1687 | 27 |
Breast cancer-specific survival | ||
 Breast cancer related deaths | 1335 | 21 |
 Deaths due to other cause | 148 | 2 |
 Alive | 4765 | 77 |
Relapse-free survival | ||
 Events | 1888 | 30 |
 Censored | 4360 | 70 |
Triple negative status | ||
 No (ER+ and HER2–) | 2321 | 37 |
 Yes (ER–, PGR– or unknown, and HER2–) | 1242 | 20 |
 Missing | 2685 | 43 |
ECOG performance status | ||
 0 | 5232 | 84 |
 ≥ 1 | 683 | 11 |
 Missing | 333 | 5 |
Tumour size, mm | ||
 0–20 | 2195 | 35 |
 21–50 | 3375 | 54 |
 > 50 | 475 | 8 |
 Missing | 203 | 3 |
Tumour grade | ||
 1 | 146 | 2 |
 2 | 2206 | 35 |
 3 | 3654 | 59 |
 Missing | 242 | 4 |
Menopausal status | ||
 Pre/peri | 3480 | 56 |
 Post | 2200 | 35 |
 Missing | 568 | 9 |
BMI | ||
 Underweight (<18.5) | 69 | 1 |
 Healthy weight (18.5 to <25) | 2503 | 40 |
 Overweight (25 to <30) | 2088 | 33 |
 Obese (≥30) | 1469 | 24 |